IndraLab

Statements


TP53 activates USP9X. 1 / 1
| 1

reach
"In conclusion, the present study confirms that WP1130 co-treatment increases cisplatin cytotoxicity by stabilizing p53 and reducing p53 ubiquitination mediated degradation in a USP9X dependent manner."